Biological Knowledge Graph Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 400.0 million
Estimated Base Value
2035 Forecast
US$ 700.0 million
Projected Market Value
CAGR 2026–2035
5.8%
Compound Annual Growth
Largest Segment
Knowledge Graph Software Platforms
Fastest Growing Segment
Knowledge Graph as a Service
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
22.5% market share
Key Players
Recursion Pharmaceuticals
Emerging Players
Causaly, Nference
Market Definition & Overview
The Biological Knowledge Graph Market comprises technologies, platforms, and services dedicated to creating, managing, and leveraging interconnected networks of biological entities and their relationships. These graphs integrate disparate biological data sources, including genes, proteins, diseases, drugs, pathways, and scientific literature, to facilitate advanced querying, inference, and discovery. This market serves pharmaceutical companies, biotechnology firms, academic research institutions, and clinical research organizations by enabling accelerated drug discovery, biomarker identification, precision medicine initiatives, and complex systems biology research through enhanced data integration and knowledge extraction capabilities within the bioinformatics industry.
Scope
- Global geographic coverage, encompassing all major regions.
- Focus on software platforms, data integration services, and consulting solutions.
- Market analysis covering the period from 2023 to 2030.
Inclusions
- Dedicated biological knowledge graph software platforms.
- Services for biological data integration, curation, and modeling.
- AI/ML tools specifically for biological knowledge graph analysis and inference.
- Knowledge graph visualization and querying interfaces tailored for biological data.
- Professional consulting and implementation services for biological knowledge graphs.
- Pre-populated biological knowledge bases and ontologies utilized within graphs.
Exclusions
- General-purpose knowledge graph solutions without specific biological domain specialization.
- Traditional relational databases, NoSQL databases, or data warehouses without graph capabilities.
- Basic bioinformatics tools for sequence analysis, alignment, or protein structure prediction.
- Clinical data management systems or electronic health records without explicit knowledge graph structures.
- Knowledge graphs developed for non-biological domains such as finance, social media, or logistics.
Market Size Forecast
Executive Summary
• The Biological Knowledge Graph market is valued at $400.0 Mn in 2025 and is forecast to reach $700.0 Mn by 2035, reflecting a robust CAGR of 5.8% as demand accelerates across every major segment and region over the ten-year outlook.
• Knowledge Graph Software Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 35.0%, while Emerging Areas is expanding the fastest at a 10.5% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 22.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• The accelerating adoption of AI in drug discovery and personalized medicine is the primary catalyst driving significant expansion and sophistication within the biological knowledge graph market, especially in advanced research.
• The market is experiencing increasing consolidation, with larger tech firms and established life science companies acquiring niche players to integrate advanced graph capabilities, intensifying competitive pressure across segments.
• Evolving regulatory frameworks for data sharing and privacy, coupled with FAIR data principles, are fundamentally reshaping data governance and interoperability demands for biological knowledge graph solutions globally.
• North America and Europe lead in innovation and adoption due to robust R&D ecosystems and significant investment in precision medicine, while Asia-Pacific presents emerging strategic growth opportunities for specialized providers.
• Strategic investments are increasingly focused on solutions that enhance data fusion from diverse omics and real-world data sources, signifying a shift towards comprehensive, integrated biological insights platforms.
• Future market success hinges on providers’ ability to offer scalable, explainable AI-driven knowledge graph solutions capable of seamlessly integrating multi-modal data for actionable therapeutic insights.
Key Market Takeaways
Critical findings and data points from this market research study.
Base Year Valuation
The Biological Knowledge Graph market was valued at $0.4 billion in the base year, reflecting its foundational presence within the bioinformatics industry.
Projected Market Expansion
This market is projected to significantly grow, reaching $0.7 billion by the forecast year.
Robust Growth Outlook
A strong Compound Annual Growth Rate (CAGR) of 5.8% underpins the steady and healthy expansion anticipated for the Biological Knowledge Graph market.
Drug Discovery Leadership
The drug discovery and development segment is expected to emerge as a leading application area, driven by increasing demands for integrated biological insights.
North American Dominance
North America is projected to maintain a dominant share in the Biological Knowledge Graph market, fueled by extensive R&D investments and technological adoption.
AI Integration Trend
The growing integration of artificial intelligence and machine learning for enhanced data analysis and predictive modeling represents a notable trend shaping market development.
Market Dynamics
Market Trends
- Increased adoption of AI/ML in knowledge graph construction is evident.
- Growing focus on integrating diverse omics data into unified graphs.
- Shift towards cloud-native and scalable graph database solutions.
- Emphasis on explainable AI and semantic reasoning within graphs.
Growth Drivers
- Accelerating demand for efficient drug discovery and development.
- Need for personalized medicine and precision healthcare solutions.
- Surge in complex biological data requiring structured representation.
- Improved data integration and interoperability across life sciences.
Restraints
- Integrating diverse, heterogeneous biological data sources remains highly complex.
- Ensuring high data quality and consistency across multiple datasets is difficult.
- Lack of standardized ontologies and data formats impedes broader adoption.
- High costs associated with data curation, graph building, and maintenance are prohibitive.
Opportunities
- Expansion into new therapeutic areas like rare diseases.
- Integration with clinical decision support systems for patient care.
- Development of advanced predictive models for drug repurposing.
- Creation of collaborative platforms for biomedical research consortia.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Knowledge Graph Software PlatformsData Integration and Curation SolutionsKnowledge Graph as a ServiceConsulting and Professional ServicesPre-Built Biological Knowledge Graphs |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesAcademic & Research InstitutionsContract Research OrganizationsDiagnostic LaboratoriesGovernment & Regulatory Bodies |
| By Application | Drug Discovery & DevelopmentPrecision MedicineDisease Understanding & PathogenesisBiomarker IdentificationTarget Identification & ValidationDrug RepurposingClinical Research & Trial Optimization |
| By Technology | Graph Database TechnologySemantic Web TechnologiesNatural Language ProcessingMachine Learning & Artificial IntelligenceData Visualization ToolsCloud Computing Infrastructure |
| By Deployment | On-Premise DeploymentPublic Cloud DeploymentPrivate Cloud DeploymentHybrid Cloud Deployment |
| By Data Source Type | Scientific Literature & PublicationsPublic Biological DatabasesProprietary & Experimental DataElectronic Health RecordsClinical Trial DataGenomics & Proteomics Data |
Regional Analysis
- North America dominates the Biological Knowledge Graph market, driven by extensive R&D investments, strong presence of leading pharmaceutical and biotech companies, and advanced technological infrastructure. Early adoption of AI/ML in drug discovery and precision medicine further establishes its leadership.
- Asia-Pacific is the fastest-growing region, primarily due to increasing government investments in life sciences R&D and the rapid expansion of its biotechnology and pharmaceutical sectors. A large patient pool and improving healthcare infrastructure are also significant growth drivers.
- In Europe, a noteworthy trend is the emphasis on collaborative, cross-border research initiatives aimed at data standardization and integration across diverse healthcare systems. This focus supports the development of unified knowledge graphs, accelerating advancements in personalized medicine and rare disease diagnostics.
Asia Pacific
9.0% CAGR
$140.0 Mn
35% share
- Asia Pacific represents a developing share of this market, with growth shaped by regional demand and investment trends.
North America
7.7% CAGR
$113.6 Mn
28.4% share
- A mature market characterized by leading pharmaceutical and biotechnology companies, advanced research infrastructure, and substantial venture capital funding for innovative bioinformatics solutions.
- Strong academic-industry collaborations also contribute to market expansion.
Europe
7.5% CAGR
$96.4 Mn
24.1% share
- Benefits from robust governmental support for life sciences research, a well-established pharmaceutical industry, and increasing adoption of knowledge graph technologies for personalized medicine and drug development.
- Data privacy regulations can influence market dynamics.
Latin America
8.9% CAGR
$23.2 Mn
5.8% share
- Experiencing steady growth due to rising investments in healthcare infrastructure and increasing awareness of precision medicine.
- Expanding partnerships with international biotech firms and academic institutions are fostering market development.
Middle East & Africa
9.2% CAGR
$17.2 Mn
4.3% share
- Emerging as a significant growth region with rising government initiatives to diversify economies through healthcare and biotech R&D.
- Increased funding for genomics projects and digital health transformation are key drivers.
Emerging Areas
10.5% CAGR
$9.6 Mn
2.4% share
- While currently holding the smallest market share, these nascent geographies show the highest growth potential due to increasing internet penetration, burgeoning scientific collaborations, and a growing focus on developing local biotech capabilities.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $90.0 Mn | 8.8% | The U.S. leads in biotech R&D, pharmaceutical innovation, and extensive adoption of bioinformatics, driven by significant funding for genomics and precision medicine initiatives across academic and corporate sectors. |
| 2 | Brazil | $4.4 Mn | 7.2% | As the largest economy in South America, Brazil has significant research in genomics and biodiversity, with a developing pharmaceutical market increasingly adopting digital health and bioinformatics solutions. |
| 3 | Germany | $31.2 Mn | 7.9% | Germany's large pharmaceutical market, strong academic research in bioinformatics and systems biology, and growing biotech sector emphasize digitalization in healthcare, making it a key player. |
| 4 | China | $58.8 Mn | 10.5% | China is driving massive genomics projects and boasts rapidly growing pharmaceutical and biotech industries, supported by significant government investment in AI and big data for health applications. |
| 5 | Saudi Arabia | $3.6 Mn | 9.5% | Saudi Arabia exhibits substantial government investment in healthcare infrastructure and genomics research, notably the Saudi Human Genome Program, aiming to diversify its economy through advanced biotech. |
Countries Covered (21)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Recursion Pharmaceuticals | 5.7% | Combine AI, automation, and wet-lab experimentation to rapidly discover and develop new medicines for rare diseases and oncology. | Operates one of the largest automated wet-labs globally, generating a massive proprietary biological and chemical dataset. | Formed a significant strategic collaboration with NVIDIA to accelerate AI model training for drug discovery. | Recursion OSRecursion DiscoveryRX-33161 |
| 2 | BenevolentAI | 5.4% | Utilize AI-driven drug discovery to identify novel targets, understand disease biology, and accelerate drug development in multiple therapeutic areas. | A pioneer in applying AI to drug discovery, leading to several molecules entering clinical development. | Announced a strategic partnership with the National Institutes of Health (NIH) to advance drug discovery for rare diseases. | Benevolent PlatformBenevolentAI Drug DiscoveryBenevolentAI Precision Medicine |
| 3 | Insilico Medicine | 5.1% | Leverage end-to-end AI platforms for target discovery, molecule generation, and clinical trial prediction to bring novel drugs to market faster. | Developed the first AI-discovered and AI-designed drug, ISM001-055 for IPF, to reach Phase 2 clinical trials. | Expanded its global footprint by opening new R&D centers and securing significant funding rounds. | Pharma.AITargetIDChemistry42+1 |
| 4 | Exscientia | 4.9% | Use AI to accelerate drug discovery and development, from target identification to clinical candidate selection, focusing on oncology and immunology. | The first company to take an AI-designed drug into human clinical trials (DSP-1181). | Entered into a new strategic research collaboration with Sanofi to discover and develop small molecule drug candidates. | Exscientia AI PlatformEXS-21546DSP-0038 |
| 5 | Healx | 4.6% | Apply AI and machine learning to identify and repurpose existing drugs for rare diseases, accelerating treatments for underserved patients. | Specializes exclusively in rare disease drug discovery, often finding new uses for approved compounds. | Advanced its lead program for Fragile X syndrome, showing promising preclinical results. | HealnetHealx AI PlatformDrug Repurposing Programs |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Recursion Pharmaceuticals, BenevolentAI, Insilico Medicine, Exscientia, Healx, Valo Health, Insitro, Tempus, SOPHiA GENETICS, QIAGEN, Clarivate, Ontotext, Eagle Genomics, PathAI, Genialis, Freenome, Graphext, Phesi, Meldia, Atomwise
The global Biological Knowledge Graph market features a competitive landscape led by Recursion Pharmaceuticals, BenevolentAI, Insilico Medicine, Exscientia, Healx, and Valo Health, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Recursion Pharmaceuticals
BenevolentAI
Insilico Medicine
Exscientia
Healx
Valo Health
Insitro
Tempus
SOPHiA GENETICS
QIAGEN
Clarivate
Ontotext
Eagle Genomics
PathAI
Genialis
Freenome
Graphext
Phesi
Meldia
Atomwise
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Tempus AI Commences IPO to Drive Precision Medicine Innovations
Tempus AI, a leader in AI-powered precision medicine, announced its initial public offering (IPO), signaling robust investor confidence and a significant capital infusion to expand its vast multimodal data platform and biological knowledge graph for drug discovery and patient care.
Google Cloud and Recursion Pharmaceuticals Forge Strategic Partnership
Google Cloud and Recursion Pharmaceuticals entered a multi-year strategic partnership to accelerate AI-driven drug discovery. The collaboration leverages Google Cloud's AI infrastructure with Recursion's extensive biological and chemical datasets and proprietary knowledge graph to identify novel therapeutic candidates.
LifeMine Therapeutics Secures $175M Series C Funding for Novel Drug Discovery
LifeMine Therapeutics successfully closed a $175 million Series C funding round. The investment will fuel the advancement of its pioneering 'Evolutionary Knowledge-guided Drug Discovery' platform, which uses a comprehensive biological knowledge graph to discover drugs from fungal secondary metabolites.
SciBite Releases TERMite 6.0, Enhancing Semantic Enrichment for Life Sciences
SciBite, a leading provider of semantic AI solutions, launched TERMite 6.0, a significant update to its core entity recognition and extraction platform. This enhancement bolsters the ability to precisely organize and connect complex biomedical data, crucial for building and querying sophisticated biological knowledge graphs.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $400.0 Mn |
| Market Size (Forecast) | $700.0 Mn |
| CAGR | 5.8% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 21 Countries |
| Segments Covered | 6 Segments, 34 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included